Dr. Sabine Mueller, MD, PhD

PNOC Co-Founder, Project Lead

Dr. Sabine Mueller is a pediatric neuro-oncologist at UCSF whose work spans translational and late effects research in pediatric and young adult brain tumor care. She co-founded and leads the Pediatric Neuro-Oncology Consortium (PNOC), an international network running biology-driven, early-phase clinical trials for children and young adults. Her research focuses on biology driven trials for pediatric and young adult brain tumors with a focus on diffuse midline glioma (including DIPG), survivorship and neurocognitive outcomes. Dr. Mueller also collaborates globally through PNOC and the Children’s Brain Tumor Network (CBTN) as well as co-leading the Brain Tumor Committee of the European based Innovative Therapies for Children and Adolescents (ITCC) consortium.

Education

Education

  • MS, University of Hamburg, Germany

  • MD/PhD, University of Hamburg

  • Internship, Pediatrics, Harvard Medical School / Massachusetts General Hospital

  • Residency, Pediatrics, Harvard Medical School / Massachusetts General Hospital

  • Fellowship, Child Neurology, UCSF

  • Fellowship, Neuro-Oncology, UCSF

Certifications

Certifications

  • American Board of Pediatrics, Pediatrics 

  • American Board of Psychiatry and Neurology, Neurology with Special Qualification in Child Neurology

  • United Council for Neurological Subspecialties (UCNS) - Neuro-Oncology

Awards

Awards & Recognition

  • BRAIN SPORE Career Development Award (2011)

  • Hellman Family Research Fellow (2012)

  • University of California Cancer Coordinating Committee Award (2012)

  • Award Winning Abstract Annual Meeting of the Society of Neuro-Oncology (2013)

  • UCSF Pediatric Fellow Mentorship Award (2017)

  • UCSF Medical Center Exceptional Physician Award (2017)

Research & Publications

Selected Research & Clinical Publications

  • Yu B, Kline C, Hoare O, et al. Measles oncolytic virus as an immunotherapy for recurrent/refractory pediatric medulloblastoma and atypical teratoid/rhabdoid tumor: Results from PNOC005. Clin Cancer Res. 2025;31(12):e3721. doi:10.1158/1078-0432.CCR-24-3721. Available from: https://pubmed.ncbi.nlm.nih.gov/40540301/

  • Kline C, Jain P, Kilburn L, et al. Upfront biology-guided therapy in diffuse intrinsic pontine glioma: Therapeutic, molecular, and biomarker outcomes from PNOC003. Clin Cancer Res. 2022;28(18):3965–3978. doi:10.1158/1078-0432.CCR-22-0803. Available from: https://pubmed.ncbi.nlm.nih.gov/35852795/

  • Haas-Kogan DA, Aboian MS, Minturn JE, Leary SES, Abdelbaki MS, Goldman S, Elster JD, Kraya A, Lueder MR, Ramakrishnan D, von Reppert M, Liu KX, Rokita JL, Resnick AC, Solomon DA, Phillips JJ, Prados M, Molinaro AM, Waszak SM, Mueller S. Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 Trial. J Clin Oncol. 2024 Feb 1;42(4):441-451. PubMed Central PMCID: PMC10824388. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10824388/

  • Mueller S, Kline C, Stoller S, Lundy S, Christopher L, Reddy AT, Banerjee A, Cooney TM, Raber S, Hoffman C, Luks T, Wembacher-Schroeder E, Lummel N, Zhang Y, Bonner ER, Nazarian J, Molinaro AM, Prados M, Villanueva-Meyer JE, Gupta N. PNOC015: Repeated convection-enhanced delivery of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma. Neuro Oncol. 2023 Nov 2;25(11):2074-2086. PubMed Central PMCID: PMC10628948. Kline C, Jain P, Kilburn L, Bonner ER, Gupta N, Crawford JR, Banerjee A, Packer RJ, Villanueva-Meyer J, Luks T, Zhang Y, Kambhampati M, Zhang J, Yadavilli S, Zhang B, Gaonkar KS, Rokita JL, Kraya A, Kuhn J, Liang W, Byron S, Berens M, Molinaro A, Prados M, Resnick A, Waszak SM, Nazarian J, Mueller S. Upfront Biology-Guided Therapy in Diffuse Intrinsic Pontine Glioma: Therapeutic, Molecular, and Biomarker Outcomes from PNOC003. Clin Cancer Res. 2022 Sep 15;28(18):3965-3978. PubMed Central PMCID: PMC9475246. Mueller S, Taitt JM, Villanueva-Meyer JE, Bonner ER, Nejo T, Lulla RR, Goldman S, Banerjee A, Chi SN, Whipple NS, Crawford JR, Gauvain K, Nazemi KJ, Watchmaker PB, Almeida ND, Okada K, Salazar AM, Gilbert RD, Nazarian J,Molinaro AM, Butterfield LH, Prados MD, Okada H. Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. J Clin Invest. 2022 Jun 15;132(12) PubMed Central PMCID: PMC9203080. Available from: https://pubmed.ncbi.nlm.nih.gov/35703183/

For a complete list of published work:

https://www.ncbi.nlm.nih.gov/myncbi/sabine.mueller.1/bibliography/public/